HSP

Sanofi-Aventis (SNY, SAN.FR) Friday said a U.S. court has banned India-based Sun Pharmaceuticals (524715.BY) from selling a generic copy of the French drug maker's cancer medicine Eloxatin from late June through mid-2012.

Sanofi earlier this month settled a series of patent infringement suits with other generic drug makers of the drug.

Copycat versions of Eloxatin were launched last August in the U.S. after a court there in June ruled that generic drugmakers who had challenged the Eloxatin patent did not infringe Sanofi's patents. Generic alternatives ate into the company's business, and Eloxatin sales last year dropped 35% to EUR957 million from a year earlier.

Earlier this year, Sanofi settled patent-infringement suits related to Eloxatin with Israel-based Teva Pharmaceutical Industries Ltd (TEVA), Germany's Fresenius Kabi Oncology Ltd. (532545.BY), Novartis AG's (NVS) generics unit Sandoz of Switzerland, Hospira Inc's (HSP) Mayne Pharma Ltd, Par Pharmaceutical Companies Inc (PRX) and its partner MN Pharmaceuticals, and Iceland-based Actavis.

The six generic drug makers will stop selling unauthorized versions of Eloxatin, whose generic name is oxaliplatin, in the U.S. between June 30, 2010 and August 9, 2012, after which the companies can sell their products under license.

Sanofi Friday said the order to stop Sun Pharmaceuticals from selling its generic version of Eloxatin came from U.S. District Court for the District of New Jersey. By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 17 73; mimosa.spencer@dowjones.com

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024